Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma.

Piotr Łacina,Aleksandra Butrym,Grzegorz Mazur,Katarzyna Bogunia-Kubik,Diana Frontkiewicz

doi:10.3390/cimb44010026

Abstract

CD147 (basigin, BSG) is a membrane-bound glycoprotein involved in energy metabolism that plays a role in cancer cell survival. Its soluble form is a promising marker of some diseases, but it is otherwise poorly studied. CD147 is overexpressed in multiple myeloma (MM) and is known to affect MM progression, while its genetic variants are associated with MM survival. In the present study, we aimed to assess serum soluble CD147 (sCD147) expression as a potential marker in MM. We found that sCD147 level was higher in MM patients compared to healthy individuals. It was also higher in patients with more advanced disease (ISS III) compared to both patients with less advanced MM and healthy individuals, while its level was observed to drop after positive response to treatment. Patients with high sCD147 were characterized by worse progression-free survival. sCD147 level did not directly correlate with bone marrow CD147 mRNA expression. In conclusion, this study suggests that serum sCD147 may be a prognostic marker in MM.

Highlights

Multiple myeloma (MM) is an incurable bone marrow malignancy associated with the presence of atypical plasma cells and with occurrence of end organ damage
We recently showed thatsCD147 is overexpressed in acute myeloid leukaemia (AML) patients compared to healthy individuals and that high CD147 is associated with worse overall survival [39]
Serum Soluble CD147 Is Increased in MM Patients

Summary

Introduction

Multiple myeloma (MM) is an incurable bone marrow malignancy associated with the presence of atypical plasma cells and with occurrence of end organ damage. It is the second most common haematological malignancy and accounts for 2% of all cancer cases [1,2]. CD147, known as basigin (BSG) and extracellular matrix metalloproteinase inducer (EMMPRIN), is a heavily glycosylated member of the Ig superfamily. It is encoded by the BSG gene located on chromosome 19p13.3 and is ubiquitously expressed on various types of cells [6,7]. Recent reports indicate that it may function as an alternative entry receptor for the SARS-CoV-2 virus associated with the COVID-19 pandemic [14,15]

Objectives

Methods

Results